Remission in psoriatic arthritis: is it possible and how can it be predicted?
AuthorsSaber, Tajvur P
Ng, C T
Lynch, Bernadette M
Walsh, Ceara A E
Veale, Douglas J
AffiliationDepartment of Rheumatology, Dublin Academic Medical Centre, St Vincent's University Hospital, and The Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Elm Park, Dublin 4, Ireland.
Outcome Assessment (Health Care)
Predictive Value of Tests
Receptors, Tumor Necrosis Factor
Tumor Necrosis Factor-alpha
MetadataShow full item record
CitationRemission in psoriatic arthritis: is it possible and how can it be predicted? 2010, 12 (3):R94 Arthritis Res. Ther.
JournalArthritis research & therapy
AbstractSince remission is now possible in psoriatic arthritis (PsA) we wished to examine remission rates in PsA patients following anti tumour necrosis factor alpha (TNFalpha) therapy and to examine possible predictors of response.
Analysis of a prospective patient cohort attending a biologic clinic, between November 2004 and March 2008, was performed prior to commencing therapy and at regular intervals. Baseline clinical characteristics including demographics, previous disease-modifying antirheumatic drug (DMARD) response, tender and swollen joint counts, early morning stiffness, pain visual analogue score, patient global assessment, C reactive protein (CRP) and health assessment questionnaire (HAQ) were collected.
A total of 473 patients (152 PsA; 321 rheumatoid arthritis (RA)) were analyzed. At 12 months remission, defined according to the disease activity score using 28 joint count and CRP (DAS28-CRP), was achieved in 58% of PsA patients compared to 44% of RA patients, significant improvement in outcome measures were noted in both groups (P<0.05). Analysis of a subgroup of PsA and RA patients matched for DAS28-CRP at baseline also showed higher numbers of PsA patients achieving remission. Linear regression analysis identified the HAQ at baseline as the best predictor of remission in PsA patients (P<0.001).
DAS28 remission is possible in PsA patients at one year following anti-TNF therapy, at higher rates than in RA patients and is predicted by baseline HAQ.
- Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
- Authors: Barra L, Pope JE, Payne M
- Issue date: 2009 Jul
- Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study.
- Authors: Mancarella L, Bobbio-Pallavicini F, Ceccarelli F, Falappone PC, Ferrante A, Malesci D, Massara A, Nacci F, Secchi ME, Manganelli S, Salaffi F, Bambara ML, Bombardieri S, Cutolo M, Ferri C, Galeazzi M, Gerli R, Giacomelli R, Grassi W, Lapadula G, Cerinic MM, Montecucco C, Trotta F, Triolo G, Valentini G, Valesini G, Ferraccioli GF, GISEA group.
- Issue date: 2007 Aug
- Body mass does not affect the remission of psoriatic arthritis patients on anti-TNF-α therapy.
- Authors: Iannone F, Fanizzi R, Scioscia C, Anelli MG, Lapadula G
- Issue date: 2013
- The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
- Authors: Heiberg MS, Koldingsnes W, Mikkelsen K, Rødevand E, Kaufmann C, Mowinckel P, Kvien TK
- Issue date: 2008 Feb 15
- Effectiveness of a third tumor necrosis factor-α-blocking agent compared with rituximab after failure of 2 TNF-blocking agents in rheumatoid arthritis.
- Authors: Blom M, Kievit W, Donders AR, den Broeder AA, Straten VH, Kuper I, Visser H, Jansen TL, Brus HL, Branten AJ, van de Laar MA, van Riel PL
- Issue date: 2011 Nov